Resmed Inc (NYSE: RMD) has reported E.P.S. of $1.99 for its fourth fiscal quarter (ending June 30) versus $1.56 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $6.94 compared to $6.12 a year ago.
Recent Price Action
On 8/1/24, Resmed Inc (NYSE: RMD) stock rose modestly by 0.6%, closing at $214.56. Moreover, this advance was accompanied by above average trading volume at 135% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 4.1% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, RMD is expected to continue to be a modest Value Builder.
Resmed has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Resmed has a very low Appreciation Score of 11 but a good Power Rating of 82, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment